Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanogen gets patent for enhancing molecular reactions:

This article was originally published in Clinica

Executive Summary

Molecular and POC diagnostic products maker Nanogen has received a US patent relating to a technology that enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridisation and amplification, antibody and antigen reactions. The system described in the patent is at the core of Nanogen's electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications. It greatly enhances the rate and specificity of the molecular biological reaction, said the San Diego, California firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel